Business ❯ Pharmaceuticals ❯ Drug Development

Clinical Trials

FDA Approval Obesity Treatments Weight Loss Drugs Market Impact Regulatory Approval Moderna Phase 3 Trials Cancer Treatments Myotonic Dystrophy Bayer Synthetic Psilocybin Eli Lilly Schizophrenia Treatments Obesity Drugs Combination Therapy Merck CagriSema Gilead Sciences AZD5904 Immunoglobulin A Nephropathy Phase I Trial Phase II Trial Weight Loss Treatments Market Analysis Neuropsychiatry Liver Therapies Market Competition Polilaminina Regulatory Approvals Obexelimab Weight Loss Medications Psychoactive Drugs Market Potential RNA-based Therapies Asundexian Efficacy Studies Regulatory Submissions Phase III Trials Preclinical Research Zaltenibart Atezolizumab Anti-inflammatory Drugs Hemophilia Treatments Biomarkers Prostate Cancer Therapeutics Alzheimer's Disease Hair Loss Treatments Acasunlimab Partnerships Azetukalner Foundayo Psilocybin Therapy Eli Lilly and Company AI in Drug Discovery Tonix Pharmaceuticals Novo Nordisk Oncology Experimental Drugs Schizophrenia Prostate Cancer Therapies Oral Treatments Outlicensing CS2009 B-cell Malignancies Bexobrutideg Tourette Syndrome Market Approval Phase Three Trials Angelman Syndrome Collaboration Agreements Cardiovascular Drugs Cholesterol Drugs Neuromuscular Diseases

Xenon Submits NDA for Epilepsy Drug as Psychiatric Trials Pause After Safety Signals

The enrollment halt raises doubt that dosing changes can cut neuropsychiatric side effects without reducing efficacy.

Novartis Faces Investor Backlash After Second Late‑Stage Trial Failure

Novartis’ Del‑Desiran Misses Phase III and Triggers Large Share Selloff

Novartis' Pelacarsen Fails Phase 3 After Lowering Lp(a)

Ultragenyx Phase 3 Angelman Drug Fails to Show Benefit

FDA Approves First Broad RAS Inhibitor for Metastatic Pancreatic Cancer

BioMarin to Buy Alesta for $275 Million to Add Oral HPP Drug

AstraZeneca Licenses Global Rights to Zegfrovy From Dizal

Definium’s Oral LSD Pill Meets Primary Endpoint in Phase 3 Depression Trial

Roche and Nurix Strike $700M Deal to Co‑Develop Oral BTK Degrader Bexobrutideg

Zealand Pharma Shares Tumble After Survodutide Phase III Shows High Dropouts

Lilly Secures Global Rights to Hanmi’s Sonefpeglutide

Vertex’s IgA Nephropathy Drug Hits Phase 3 Goals, FDA Filing Slated for March

Lilly’s Taltz Plus Zepbound Outperforms Taltz Alone in Phase 3b Psoriasis-Obesity Trial

Compass Pathways’ Psilocybin Therapy Hits Phase 3 Goal in Treatment-Resistant Depression

GSK and Ionis Report Phase 3 Success for Hepatitis B Drug, Plan Q1 Filings

Genmab Halts Acasunlimab to Focus on Late-Stage Cancer Portfolio

Kymera Jumps on KT-621 Phase 1b Win, Advancing Oral STAT6 Degrader Into Phase 2b

Bristol Myers Delays ADEPT-2 Alzheimer’s Psychosis Readout to 2026 After Site Irregularities

Multiple Firms File Securities Class Actions Against Telix in Indiana Federal Court Over Prostate Cancer Program Disclosures